| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 79, 1334-1341, Copyright © 1994 by Endocrine Society
ARTICLES |
S Kenouch, M Lombes, F Delahaye, E Eugene, JP Bonvalet and N Farman
INSERM U-246, Faculte de Medecine Xavier Bichat, Paris, France.
The expression of mineralocorticoid receptors (MR) and 11 beta- hydroxysteroid dehydrogenase (11HSD) activity has been investigated in the epidermis and appendages of the human skin. Aldosterone binds to MR and regulates sodium transport in tight epithelia. Mineralocorticoid selectivity is achieved through coexpression of MR and 11HSD, which prevents permanent MR occupancy by glucocorticoids. Some forms of hypertension may involve abnormalities of MR and/or 11HSD. However, their direct assessment in humans remains difficult in the kidney or colon. This led us to explore this system in human skin easily accessible to biopsy. In situ hybridization with specific MR complementary ribonucleic acid probes and immunohistochemistry using three different anti-MR antibodies showed that MR was expressed at both the messenger ribonucleic acid and protein levels in the keratinocytes of the epidermis, in the sweat and sebaceous glands, and in the hair follicles. A significant 11HSD activity was found in isolated sweat gland ducts (5 fmol/3-mm length.10-min incubation with 10 nmol/L corticosterone as substrate) and was very low in the epidermis. In both structures, reductase activity was 10 times lower than that of dehydrogenase. Studies on the cofactor specificity of the enzyme showed a nicotinamide-adenine-dinucleotide preference in sweat glands, contrasting with a nicotinamide-adenine-dinucleotide phosphate dependence in epidermis. Human skin appears as a new target for aldosterone because it coexpresses MR and 11HSD. Our findings present the possibility to explore the functionality of the MR system in human tissue and its implications in various physiopathological situations.
This article has been cited by other articles:
![]() |
Y. Sainte Marie, A. Toulon, R. Paus, E. Maubec, A. Cherfa, M. Grossin, V. Descamps, M. Clemessy, J.-M. Gasc, M. Peuchmaur, et al. Targeted Skin Overexpression of the Mineralocorticoid Receptor in Mice Causes Epidermal Atrophy, Premature Skin Barrier Formation, Eye Abnormalities, and Alopecia Am. J. Pathol., September 1, 2007; 171(3): 846 - 860. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Z. Lu, S. E. Wardell, K. L. Burnstein, D. Defranco, P. J. Fuller, V. Giguere, R. B. Hochberg, L. McKay, J.-M. Renoir, N. L. Weigel, et al. International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors Pharmacol. Rev., December 1, 2006; 58(4): 782 - 797. [Full Text] [PDF] |
||||
![]() |
N. Draper and P. M Stewart 11{beta}-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action J. Endocrinol., August 1, 2005; 186(2): 251 - 271. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bocchi, S. Kenouch, M. Lamarre-Cliche, M. Muffat-Joly, M. H. Capron, J. Fiet, G. Morineau, M. Azizi, J. P. Bonvalet, and N. Farman Impaired 11-{beta} Hydroxysteroid Dehydrogenase Type 2 Activity in Sweat Gland Ducts in Human Essential Hypertension Hypertension, April 1, 2004; 43(4): 803 - 808. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ngarmukos and R. J. Grekin Nontraditional aspects of aldosterone physiology Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1122 - E1127. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Farman and M.-E. Rafestin-Oblin Multiple aspects of mineralocorticoid selectivity Am J Physiol Renal Physiol, February 1, 2001; 280(2): F181 - F192. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Slominski and J. Wortsman Neuroendocrinology of the Skin Endocr. Rev., October 1, 2000; 21(5): 457 - 487. [Abstract] [Full Text] |
||||
![]() |
G. Hirasawa, H. Sasano, T. Suzuki, J. Takeyama, Y. Muramatu, K. Fukushima, N. Hiwatashi, T. Toyota, H. Nagura, and Z. S. Krozowski 11{beta}-Hydroxysteroid Dehydrogenase Type 2 and Mineralocorticoid Receptor in Human Fetal Development J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1453 - 1458. [Abstract] [Full Text] |
||||
![]() |
G. Hirasawa, H. Sasano, K.-i. Takahashi, K. Fukushima, T. Suzuki, N. Hiwatashi, T. Toyota, Z. S. Krozowski, and H. Nagura Colocalization of 11{beta}-Hydroxysteroid Dehydrogenase Type II and Mineralocorticoid Receptor in Human Epithelia J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3859 - 3863. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Zennaro, N. Farman, J.-P. Bonvalet, and M. Lombes Tissue-Specific Expression of {alpha} and {beta} Messenger Ribonucleic Acid Isoforms of the Human Mineralocorticoid Receptor in Normal and Pathological States J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1345 - 1352. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. White, T. Mune, and A. K. Agarwal 11{beta}-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess Endocr. Rev., February 1, 1997; 18(1): 135 - 156. [Abstract] [Full Text] |
||||
![]() |
C Roudier-Pujol, A Rochat, B Escoubet, E Eugene, Y Barrandon, J. Bonvalet, and N Farman Differential expression of epithelial sodium channel subunit mRNAs in rat skin J. Cell Sci., January 2, 1996; 109(2): 379 - 385. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |